NeuroVigil's iBrain: Revolutionizing Brain Monitoring without the Needles


NeuroVigil, a leading neurotechnology company, launched its iBrain™ Personal Brain Monitor in four US states, selling 1.4% of its stock for over $85 million. This propelled the company’s valuation to over $6 billion, making it the highest Series B financing in history. The financing, which involved 27 strategic investors, closed in just 24 minutes. Dr. Philip Low, NeuroVigil’s Chairman and CEO, emphasized the significance of non-invasive brain technology over invasive methods.

The iBrain, positioned as an investigational device, aims to detect biomarkers of conditions like apnea and aneurysms. It will initially focus on asymptomatic individuals, with no immediate therapy modifications based on the collected data. In a later phase, the iBrain 3 will target brain cancer and Parkinson’s disease, as well as assist non-communicative individuals. This project, initiated at the behest of late advisor Stephen Hawking, garnered attention for its innovative approach and secured multiple patents.

NeuroVigil is also exploring partnerships with car manufacturing conglomerates to apply Dynamic Spectral Scoring (DSS) technology in monitoring drivers and managing electric vehicle batteries. DSS, developed by Dr. Low, identifies subtle shifts in data to predict system transitions accurately. This technology, initially aimed at neuroscience, has broader implications, as evidenced by its application in various systems.

Dr. Low’s vision is to democratize access to real-time brain state monitoring. Unlike invasive brain-computer interfaces (BCIs), iBrain offers a non-invasive solution without animal testing, potentially revolutionizing neuroscience. NeuroVigil has assembled a talented team and secured substantial funding, with Dr. Low opting to reward his team with performance-based stock options.

Experts recognize NeuroVigil’s groundbreaking potential, with its technology poised to impact various industries. Dr. Low’s innovative approach has earned him accolades from MIT Technology Review, alongside recognition for NeuroVigil’s exceptional value and reputation. The company’s achievements in healthcare innovation have been widely acknowledged, with iBrain hailed as a transformative innovation by The New York Times.

Until then follow

plain logo

Contact Us:

Follow Us

Get the latest news, analysis and stories on Neurotechnology (Neurotech).

©️ 2024 Neureads | All Rights Reserved